Murwere wekuAustralia Anowana Mhinduro Inoshamisa Yekutanga Nekurapa kweBIOOCUS Medical Group's Dual CD19/CD20 CAR-T yeDLBCL Yakadzoka Muropa
Rodney Charles Monger, murume ane makore makumi matanhatu nemasere ekuberekwa wekuAustralia, akaonekwa aine chirwere che "diffuse large" chinonzi "diffuse large". B-Cell Lymphoma (DLBCL) makore matatu apfuura. Achitsvaga rubatsiro rwepamusoro, akaenda kuBIOOCUS Medical Group muna Nyamavhuvhu 2025. Kuongororwa kwe cervical lymph node biopsy kwakaratidza kuti B-cell lymphoma inopararira kubva pakati pe germinal center yakabva. Immunohistochemistry yaive yakanaka kwazvo kune CD20, CD19, uye CD10, ine Bcl-6, Bcl-2 (70%+), uye c-MYC (60%+). Kuongororwa kwemajini kwakaratidza kurongwa kweBCL2 neFISH uye mutations mumajini eEZH2, KMT2D, TNFRSF14, NRAS, uye TPMT—zviratidzo zvakajeka zvehunhu hwehasha uye hune njodzi huru.
Mushure mekugamuchira pola pamwe chete nemushonga weBTK inhibitor nelenalidomide, zvichiteverwa neFC lymphodepletion chemotherapy, chirwere chaVaMonger chakaramba chisingashande zvakanaka. Chikwata cheBIOOCUS Medical Group chakakurudzira mushonga wavo mutsva weCD19/CD20 CAR-T cell therapy.
Musi wa8 Gunyana, 2025, VaMonger vakapinzwa muropa reCD19/CD20 CAR-T cells. Zvinoshamisa kuti havana kusangana nechirwere che cytokine release syndrome (CRS) uye havana immune effect cell-associated neurotoxicity syndrome (ICANS), zvikaita kuti vagare zvakanaka mushure mekupinzwa muropa, izvo zvakavaita kuti vagare vakagadzikana uye vaine tariro kubva pazuva rekutanga.
Kuongororwa kweropa remumativi kwakaratidza kuwedzera kunoshamisa kwemasero eCAR-T, zvichiratidza kupinza uye kuwanda kwakanaka kwazvo. Pazuva rechina mushure mekuiswa, masero eCAR19+ aive 0.50% yemasero eCD3+ T (kukosha kwakakwana 6.04 × 10⁷/L) uye masero eCAR20+ aive 0.41% (4.96 × 10⁷/L). Pakazosvika zuva rechinomwe, CAR19+ yakakwira kusvika pa1.68% (1.40 × 10⁷/L) uye CAR20+ yakakwira kusvika pa1.63% (1.36 × 10⁷/L). Pazuva rechi10, CAR19+ yakasvika pa31.43% yemasero eCD3+ T (kukosha kwakakwana 3.13 × 10⁸/L) uye CAR20+ yakasvika pa32.74% (kukosha kwakakwana 3.26 × 10⁸/L). Kuyerera kwemasero eropa kwakaratidzawo kupararira kwakaringana pakati pemaCD4+ neCD8+ subsets ane CAR mbiri dzakasimba, zvichiratidza kugona kwekurapa uku kukurudzira kugara kwenguva refu uye kuwanda kwemasero aya.
Pakuongororwa kwazvino (zuva rechi10), VaMonger vanoramba vachiita zvakanaka pakurapa. Vari kutora mishonga yemuromo yakagadzirwa nemaoko inosanganisira acyclovir, compound sulfamethoxazole, orelabrutinib, lenalidomide, uye mishonga inotsigira, vachigara vachitarisa huwandu hweropa, mashandiro echiropa neitsvo, uye zviratidzo zvekuzvimba.
Chikwata cheBIOOCUS Medical Group chakapa rutsigiro rwakakwana, rwakanangana nevarwere panguva yese, kusanganisira pekugara pakanaka, chikafu chinovaka muviri, rubatsiro rwekufambisa, uye mazano epfungwa kuna VaMonger nemhuri yavo. Maitiro aya akazara akamubvumira kutarisa zvizere pakupora.
Nyaya yaVaMonger inoratidza kugona kwekurapa kweBIOOCUS Medical Group kweCD19/CD20 CAR-T kaviri kune varwere vane DLBCL yakadzoka/isina simba. Kukura nekukurumidza uye kwakasimba kwemasero eCAR-T asina chepfu zvakanyanya kunoratidza kuchengetedzeka kwakanaka kwechigadzirwa ichi uye kushanda kwakasimba kwekudzivirira bundu - kunyangwe kumurwere mukuru ane mamorekuru ane njodzi huru.